2023-08-16 08:28:58 ET
- MediciNova Inc ( NASDAQ: MNOV ) Wednesday announced it has received a Decision to Grant from the European Patent Office for a new patent which covers MN-001 (tipelukast) for the treatment of scleroderma and/or systemic sclerosis.
- This patent is expected to expire no earlier than June 2035.
- The allowed claims cover oral administration, including tablets and capsules, as well as liquid dosage forms.
- Kazuko Matsuda, Chief Medical Officer, MediciNova said, "This new patent is based on positive results from a systemic sclerosis animal model study conducted recently. The Canadian Intellectual Property Office granted a similar patent earlier this year."
- MNOV +16.88% premarket to $2.7
- Source: Press Release
For further details see:
MediciNova receives new patent covering MN-001 for the treatment of scleroderma in Europe